This is something you should read-no science no research but something to reflect at:
ESC Congress @ Rome
EuroPCR coverage 2
This is MATRIX time @ EuroPCR 2016.
I had the privilege of presenting one of the most important subsidies of the Matrix trial, PI Marco Valgimigli, assessing the role of transradial vs. transfemoral PCI either in STEMI or NSTE-ACS patients undergoing invasive management.
Results were consistent with the main publication in Lancet last year, showing a significant benefit in terms of NACE and a strong trend in terms of improvement of MACE for the transradial approach.
EuroPCR coverage 1
This is the official TCTMD report on the late-breaking clinical trial session on BVS at the latest EuroPCR.
I am proud of being part of it, presenting the short-term data of the RAI registry. And I am also proud that our centre was the second top enroller centre in both the RAI and IT-DISAPPEARS registry!
The role of DCB for recurrent ISR
Which is the most valuable treatment for recurrent in-stent restenosis, namely the ISR of 2 already implanted stents? We investigated the role of drug-coated balloons in this setting, and our findings seem to show how this strategy should be considered.
BVS SAVE: The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds for the Treatment of Small Vessel Disease
Much debate is currently running on BVS performance in small coronary vessels. I am here attaching one of the few publications available worldwide, that our group coordinated recently: the BVS SAVE study. This poster was presented at both the 2015 GISE and TCT meetings. Please take a look at the results.